The path ahead for the FDA
In a Coalition for Healthcare Communication webinar, former FDA exec Nancy Bradish Myers reflected on the agency’s tumultuous 2020 and charted a path forward for 2021.
In a Coalition for Healthcare Communication webinar, former FDA exec Nancy Bradish Myers reflected on the agency’s tumultuous 2020 and charted a path forward for 2021.
Ending the pandemic is clearly the top public-health priority for the incoming Biden administration. Will action on drug pricing, ACA reform and data privacy follow?
Washington healthcare policy insider Terry Haines offers his thoughts on COVID relief, the future of the Affordable Care Act and more.
With communities of color historically underrepresented in clinical trials, numerous groups are working to diversify COVID-19 vaccine research.
The agency sent warning letters to vape companies selling e-cigarettes without premarket authorization.
The attention to the upcoming presidential election also dims the likelihood of legislation efforts until 2021.
President Trump is putting pressure on the pharma industry ahead of the presidential election.
The House Energy and Commerce subcommittee on health began an investigation this week.
President Trump’s executive order calls for regulation to make some of the changes permanent.
Although the world is still months away from a COVID-19 vaccine, it’s imperative that pharma companies have the conversation right now about the cost of innoculation.
Please login or register first to view this content.